Interleukin 6 Receptor (IL6R) Antibody

Este producto es parte de IL6R - Interleukin 6 Receptor
Product Graph
364€ (100 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Interleukin 6 Receptor (IL6R) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx234284
tested applications
ELISA, WB, IHC, IP

Description

IL6R Antibody is a Rabbit Polyclonal against IL6R.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

CategoryPrimary Antibodies
Immunogen TargetInterleukin 6 Receptor (IL6R)
HostRabbit
ReactivityHuman, Mouse, Rat
Recommended DilutionWB: 1/500 - 1/1000, IHC: 1/50 - 1/200, IP: 1/500 - 1/1000. Optimal dilutions/concentrations should be determined by the end user.
ClonalityPolyclonal
ConjugationUnconjugated
IsotypeIgG
Purity≥ 95% (SDS-PAGE)
PurificationPurified by immunogen affinity chromatography.
Size 1100 µg
FormLiquid
Tested ApplicationsELISA, WB, IHC, IP
BufferPBS, pH 7.3, with 0.02% sodium azide and 50% glycerol.
AvailabilityShipped within 5-12 working days.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry IceNo
UniProt IDP08887
AliasIL6Q,gp80,CD126,HIES5,IL-6R,IL6RA,IL6RQ,IL-1Ra,IL-6RA,IL6QTL,IL-6R-1,L-6R-Alpha,IL-6Rα
BackgroundAntibody anti-IL6R
StatusRUO
NoteConcentration: 2 mg/ml - Validity: 12 months.

Descripción

IL6R is a key component of the interleukin-6 (IL6) signaling pathway, consisting of a membrane-bound and soluble form (sIL6R), which binds IL6 and mediates downstream effects via the gp130 co-receptor This interaction activates the JAK/STAT3, MAPK, and PI3K/AKT pathways, regulating immune responses, inflammation, and hematopoiesis IL6R signaling is critical in acute-phase responses, B cell maturation, and T cell proliferation Dysregulation of IL6R activity is implicated in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus (SLE) In cancer, IL6R signaling supports tumor progression, angiogenesis, and immune evasion Therapeutic targeting of IL6R, such as with tocilizumab, is effective in reducing inflammation and cytokine storm in conditions like COVID-19, autoimmune disorders, and hematological malignancies

Related Products

EH0202

Human IL-6Rα(Interleukin-6 receptor subunit alpha) ELISA Kit

Ver Producto
EMK0111

Monkey IL-6R ELISA Kit

Ver Producto
ER1105

Rat IL-6R(Interleukin 6 Receptor) ELISA Kit

Ver Producto